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Sllmmar~ 
The thymus leukemia antigen (TLA) is a class Ib, or 'nonclassical' class I molecule, one of several 
encoded within the T/a locus of the mouse major histocompatibility complex (MHC). It structurally 
resembles the H-2K, D, and L class I transplantation antigens, which present processed peptides 
to cytotoxic T lymphocytes (CTLs). Although their function(s) are unknown, there has been 
recent speculation concerning the possibility that class Ib molecules may present antigens to 
T  cells that express 3'6 T cell antigen receptors (TCKs).  In this report, using both a cell-cell 
adhesion assay and adhesion of T lymphocyte clones to purified plate-bound TLA, we provide 
evidence that TLA can bind to both human and mouse CDS. We also show that a chimeric 
class  I  molecule containing  the  peptide  antigen  binding  site  of L d and  the  cr  domain, 
transmembrane, and cytoplasmic segments of TLA, can support a CD8-dependent immune response 
by CTLs. These results demonstrate for the first time binding of a class Ib molecule to CD8 
with a functional outcome, as is observed for the class I transplantation antigens. The capacity 
to interact with CD8 has been conserved despite the extensive sequence divergence of TLA in 
the peptide antigen binding site, suggesting this interaction is highly significant. TLA is expressed 
by epithelial cells in the mouse small intestine. As these epithelial cells are in close contact with 
intestinal intraepithelial lymphocytes that are nearly all CD8 +, and many of which express the 
~  TCR, the data are consistent with the hypothesis that TLA is involved in antigen presentation, 
perhaps to 3~6-positive lymphocytes in this site. 
G 
enes encoding both class I and II cell surface proteins 
are located within the mouse MHC (reviewed in refer- 
ence 1). Functional class I sequences encode the transplanta- 
tion antigens that interact with both the TCK and CD8 in 
presenting peptide antigens to CTLs (2, 3). In binding class 
I transplantation antigens on target cells, the CD8 molecule 
act as a co-receptor with the TCR for antigen recognition, 
thus forming a multimolecular, intercellular complex (3). For- 
mation of this complex causes the delivery of specific signals 
to the T cell with resultant cytolysis of the target cell (reviewed 
in reference 4). 
Most of the MHC class I genes in mice do not lie within 
the K  or D  subregions where the transplantation antigens 
are encoded; rather, the majority are located within the Qa, 
T/a, and Hint subregions. Although not all of the class Ib 
genes within these subregions are capable of encoding ma- 
ture polypeptides, products of at least five of these genes have 
been identified either by immunochemical techniques or by 
measuring T  cell responses  to them (reference 5,  reviewed 
in reference 6). The functions(s) of the class Ib proteins are 
unknown, although several have been proposed including a 
role in lymphocyte differentiation, antigen presentation, and 
in the death signal involved in negative selection in the thymus 
(reviewed in references 7 and 8). It has also been suggested 
that the class Ib genes serve as a reservoir of sequences used 
to diversify the transplantation antigens, and finally, that these 
genes have no function at all (9). Regarding their proposed 
function as antigen presenting elements, several groups of 
investigators have demonstrated alloreactive, autoreactive, and 
peptide antigen specific responses by 3d~ TCR-positive lym- 
phocytes that recognize class Ib surface molecules (5, 10, 11). 
Based largely on these observations, it has been proposed that 
T lymphocytes expressing the 7/~ TCR utilize class Ib mole- 
cules as antigen presenting elements (12, 13). However,  it 
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T-call clones and hybridomas, are physiologicaUy relevant for 
immune responses  by populations of 3'/~ T  cells. 
A class Ib molecule named the thymus leukemia antigen 
(TLA)  1 is encoded by the TI8  a gene located within the Tla 
subregion (nomenclature according to reference 14). Histor- 
ically, TLA was first identified as a leukemia-specific cell sur- 
face antigen in X-irradiated A strain mice (15), although its 
expression  was soon detected in immature cortical thymo- 
cytes as well as leukemias of particular mouse strains. By in- 
spection of its gene organization and amino acid sequence, 
TLA appears similar to the transplantation antigens and con- 
tains separate exons encoding for external od, or2, and or3, 
as well as transmembrane, and cytoplasmic domains (16). Com- 
parison of the TLA amino acid sequence with an H-2 con- 
sensus sequence  shows a 60% identity in the cd domain, 
a 66% identity in the ol2 domain, and an 86% identity in 
the or3 domain (6).  TLA contains three potential sites for 
N-linked glycosylation at positions 86, 90, and 283 compared 
with H-2 consensus glycosylation sites at positions 86, 176, 
and 256 (6). Four conserved cysteines are present in TLA at 
positions 101, 164, 203,  and 259,  as is also seen in all the 
transplantation antigens (17, 18). These cysteine residues are 
required for disulphide bond formation and proper folding 
in all class I molecules.  TLA also associates noncovalently 
with 32-microglobulin, as do K, D, and L class I antigens 
(6).  Despite all these similarities  to the transplantation an- 
tigens, a ceU-mediated immune response to TLA has never 
been reported, possibly due to its low levels of expression 
outside of the thymus and intestine (19, 20).  If TLA were 
to function similarly to a transplantation antigen, perhaps 
it would also be bound simultaneously by both the TCR 
and CD8 as in the co-receptor model for antigen recogni- 
tion. To determine if this is the case, the ability of TLA to 
interact with CD8 was assessed. 
Materials and Methods 
Gene Cloning and Transfections.  A  TI~ cDNA clone was ob- 
tained from Dr. F.-W. Shen, Tampa Bay Research Institute (St. 
Petersburg, FL) Constructs pDT18ahGH and pHBApff18  d were 
generated  by standard  molecular  biology methods using pBhescript 
KS+ (Stratagene, LaJolla, CA) or pBR322-based cloning vectors. 
The H-2D a promoter, human ~-actin promoter-intervening se- 
quence 1 (IVS 1), and human growth hormone coding sequence 
DNA fragments are described elsewhere (21-23). The plasmid 
pLdneo, containing the H-2L  d promoter and genomic coding se- 
quences colinear with pSV2neo, was a gift of Dr. Martha Zuniga, 
UC Santa Cruz, Santa Cruz, CA.  A chimeric Ld/TLA MHC 
class I gene construct, designated pHBAprLT18  d, was generated 
from a 1.8-kb XbaI genomic fragment encoding the L  d leader, ~1, 
and c~2 domains and a 4.5-kb XbaI genomic fragment of pTla.1 
encoding the T/8  d c~3, transmembrane, cytoplasmic, and 3' UTR 
(16, 24). The human B-actin promoter was inserted 5' of this chi- 
meric gene in the proper orientation for expression in the cloning 
vector pBluescript KS+. 
1  Abbreviations used in  this paper: CHO, Chinese hamster ovary; IEL, 
intraepithelial lymphocyte,  TLA, thymus  leukemia antigen. 
20 #g of the appropriate construct was coelectroporated (Gene 
Transfector 300; BTX  Corp.,  San Diego,  CA) with 10 ~g of 
pSV2neo (25) into either  107 CIR B cells or L cell fibroblasts. 
G418 (Gibco BILL, Gaithersburg, MD) selection at 600/zg/ml ac- 
tive drug for CIR transfectants and 400 ~g/ml active drug for L 
cell transfectants began 48 h postelectroporation in 96 well flat- 
bottom microtiter plates. Stable transfectants were chosen at 3 to 
4 wk, grown in drug-free RPMI 1640 supplemented with 10% 
FCS, and stained for cell surface expression of TLA or L  d. Staining 
was done as previously described (20) with TL.m4 primary mAb 
(a kind gift of Drs. S.  Kimura and E. Boyse, Sloan-Kettering 
Memorial Cancer Institute, NY) followed by a FITC-conjugated 
goat anti-mouse Ig second reagent (CalTag, South San Francisco, 
CA) for detection of TLA. L  d expression was assessed using mAbs 
30-5-7 (specific for the ce2 domain of Ld), which stains both L  d 
and Ld/TLA positive transfectants, and 28-14-8 (specific for the 
or3 domain of La), which detects only L  d transfectants (26, 27). 
Cells were fixed  in 1% paraformaldehyde  and analyzed  on a Coulter 
EPICS V flow cytometer (Coulter Electronics, Inc., Hialeah, FL) 
CIR TL.J, a high expressing CIR TLA (+) transfectant, using 
the pHBAprT18  d construct, was used in both the cell-cell adhe- 
sion assays and to purify TLA glycoprotein.  L d and Ld/TLA L cell 
transfectants that express approximately  equal levels of surface  pro- 
tein, as measured  by staining and flow cytometry with mAb 30-5-7, 
were used as targets for primary CTLs. 
Cell-Cell Adhesion Assay.  This assay has been described in de- 
tail previously (3, 28, 29). Briefly, 3 to 4 d before assay between 
5  x  103 and 104 human CD8c~(+) or CD8ce(-) adherent chinese 
hamster ovary (CHO) cells per well were placed in 96 well flat- 
bottom microtiter plates. Optimal confluent monolayers,  as judged 
by visual inspection, were used on the day of assay. Parent or trans- 
fectant CIR B cells were labeled for 2 h with [3SS]methionine 
(>12.5/~Ci/l@ cells, ;>600 Ci mmol-l; Amersham, Arlington 
Heights, IL) in lx  MEM without t-methionine (Flow Laborato- 
ries, McLean, VA). The CIR cells were added to the plate wells 
and centrifuged for 3 min at 160 g to initiate contact with the 
CHO monolayers.  The plates were then incubated at 37~  for I h 
while shaking gently. Following incubation, the wells were washed 
10-12 times with assay  buffer and the remaining bound cells were 
solubilized in 1% Triton X-100 for scintillation counting. For the 
antibody blocking experiments, 106 labeled CIR cells were prein- 
cubated with 10/zg of the appropriate mAb, or adherent CHO 
cells in plate wells were preincubated with 2.5/~g of the appro- 
priate mAb. Incubations were carried out for 30 min at 4~  in 
0.01% NAN3, lx  PBS (pH 7.4) and 10% FCS ("assay buffer"). 
The mAbs used in the blocking studies were the anti-TLA mAbs 
TL.m4 and TL.m9 and the anti-CD8 mAbs 66.2 and 51.1 (28, 
30). All mAbs were protein A-Sepharose affinity-column  purified. 
Purification of Class I and Class Ib Molecules.  D  b was purified 
as described  previously (31). TLA was purified from the CIR TL.J 
transfectant according to a slightly modified version of this pro- 
tocol (31). Briefly,  cells grown in vitro were lysed  by nitrogen cavi- 
tation and the membrane fraction isolated  by centrifugation. Mem- 
branes were extracted with 0.5% Triton X-100 in 10 mM Tris (pH 
7.2) with 0.15 M NaC1, and the solubilized protein applied to a 
column prepared from the rat anti-TLA mAb HD168 (a kind gift 
of Drs. L. Old and E. Stockert, Sloan-Kettering Memorial Cancer 
Institute, NY) coupled to Sepharose 4B (32). Following loading 
and washing with extraction buffer, the column was washed with 
0.5%  deoxycholate (DOC),  10 mM Tris (pH 8.2) with 0.15 M 
NaCt (buffer 1) to remove  nonspecifically  bound protein, and TLA 
then eluted using 0.5% DOC in 15 mM sodium carbonate buffer 
(pH 11) with 0.15 M NaC1 (buffer 2). Eluted fractions were as- 
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Chemical Co., Rockford, IL), and for TLA glycoprotein by direct 
ELISA using mAb HD168 and HRP-goat anti-rat Ig second anti- 
body (CalTag; reference 31). 
Cytotoxic T  Lymphocyte (CTL) Adhesion to Plate-Bound Class I 
Major Histocompatibility Complex (MHC)  Glycoproteins.  Purified 
TLA and D b antigens were immobilized in microtiter plate wells 
by incubation  for 1.5 h at 25~  followed by four washes with 
0.15 ml of lx  PBS as previously described (31). The amount of 
input protein/weU is indicated in Fig. 3 B. The wells containing 
bound class I and class Ib molecules were then blocked by incuba- 
tion with 2% FCS; control wells received only 2% FCS. V~8 + 
CTL clones C35 and Cll, specific for the K  b class I aUoantigen 
(33, 34), were SlCr-labeled (sodium chromate, 100/~Ci/107 cells, 
250-500  mCi nag-1 Cr;  Amersham)  by incubation  for 1 h  at 
37~  Labeled ceils were then washed and added to wells bearing 
the indicated class I or class Ib protein in the absence or presence 
of soluble anti-VB8 mAb. The anti-V/38 mAb F23.1 (35) was in- 
cubated with the clones at a concentration of 0.45 #g/ml for C35 
and 0.9/~g/ml for Cll in 100/~1 total volume. Plates were then 
centrifuged at 1200  rpm for 1 rain to initiate contact and incubated 
for 2 h at 37~  5% CO2. Cell binding was determined as previ- 
ously described by adding 0.1 ml ice-cold 1￿  PBS to each well 
and placing the plates in an ice water bath for 10 min (33). Un- 
bound cells were removed by pipeting 10 times and discarding the 
supernatant.  Well bottoms were then cut off and the remaining 
radioactivity was measured. 
Cytotoxicity Assay.  Primary  anti-H-2  a effector  CTLs  were 
created by stimulating  ,'~10  s C57BL/6 splenocytes (H-2  b) with 
,~10  s 2,000 r irradiated BALB/c splenocytes (H-2a). Ceils were in- 
cubated for 5 d in RPMI 1640 supplemented with 10% FCS at 
a concentration  of 2  x  107 total splenocytes per T25 tissue cul- 
ture flask. Both C57BL/6 and BALB/c mice were bred and housed 
in the UCLA Vivarium, UCLA School of Medicine. SlCr-loading 
(100/zCi/4  x  106 cells; Amersham) of lightly trypsinized target 
cells was done for 1 h at 37~  5% CO2 with residual S~Cr re- 
moved by extensive washing. The targets included L cells trans- 
fected with  the L  a gene,  the Ld/TLA chimeric  gene,  and  the 
pSV2neo gene, along with DBA/2 strain P815 (H-2  d) mastocy- 
toma cells. Varying amounts of effector cells were incubated with 
104 labeled targets in 200/~1 of medium containing  RPMI 1640 
supplemented with 10% FCS. Target ceil lysis proceeded for 4 h 
in  96-well U-bottom microtiter plates at  37~  and  5%  CO2. 
Measurement of specific StCr release was performed as described 
previously by removing 100/zl per well and assaying for SlCr in 
the removed supernatant (36). For blocking studies, 2 ml ofeffectors 
were preincubated with 200/~1 of the anti-Lyt2.2 mAb 41-3.48 
(3.2 mg/ml, ammonium  sulfate precipitation of ascites fluid) for 
20 min at 37~  5% CO2 and then added to the microtiter plate 
assay wells (37). 
Results 
Cell-Cell  Adhesion  Assay.  A  full-length  TI8  a cDNA, 
encoding TLA serological determinants (38), was inserted 
into two different mammalian expression cassettes (Fig. 1 A). 
Transfectants were made using CIR cells that lack HLA-A 
and HLA-B genes and express only low levels of HLA-C. 
These nonadherent human B lymphoma cells were used in 
order to minimize background binding to CD8 due to en- 
dogenous human class I gene expression (28, 39, 40). Gene 
transfer and subsequent antibody staining of numerous clones 
Figure 1.  TI8  ~  cDNA expression  constructs and flow  cytometric  anal- 
ysis of CIR B cell transfectants. (,'t) Constructs pDT18dhGH (top) and 
pHflApff18  a (bottom) are shown, pBS is the cloning  vector pBluescript 
KS+. The constructs  are not drawn to scale. (B) Flow  cytometry  of  repre- 
sentative  CIR parent  and stable transfectant  lines. Staining  with the mAb 
TL.m4  is shown  (30). The mAb HD168  (32) stained  identically  to TL.m4, 
while the mAb TL.m9  (30) did not stain either  the parent or transfectants 
(data not shown). 
generated  from  each  type  of construct  showed  that  the 
fl-actin-promoter construct yields a higher level of surface 
TLA expression than does the H-2Da-promoter construct 
(Fig. 1 B). Very high levels of gene expression for several other 
class Ib genes have been achieved using this/~-actin-promoter 
expression cassette in CIR cells  (data not shown). 
The ability of TLA to bind to CD8 was measured through 
the adhesion of T/8  a transfectants to monolayers of CHO 
cells that overexpress or that are negative for human CD8c~ 
(28). Due to the previously reported weak avidity of HLA- 
A2.1-mediated CD8 binding (28), data presented here is from 
a transfectant expressing high levels of TLA surface protein 
generated using the pHflAprT18  a (fl-actin promoter) con- 
struct. However, transfectants that express lower levels of sur- 
face TLA under the control of the H-2D  d promoter also 
bind CD8 specifically,  though not as tightly, in this assay 
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Cell-cell adhesion assay. Binding of radiolabeled CIR. cells 
to CD8ol(-) and to human CD8o~(+) adherent CHO monolayers is mea- 
sured; the percentage of input CIR cells retained after extensive washing 
is presented. Cell lines CIK A2.1, CHO.1 (CDS~-negative), and CHO.4 
(CD8c~-overexpressing)  have been previously described (28, 40). Blocking 
mAbs TL.m4 and TL.m9 are both TLA-specific, but only TL.m4 recog- 
nizes the allele of TLA encoded by T18  d (30). The anti-CD8 mAb 66.2 
is characterized elsewhere (49). Error bars represent the standard devia- 
tions of triplicate samples. 
(data not shown). Both CIR TL.J (TLA-positive) and CIR 
A2.1 (HLA-A2.1-positive)  transfectants  bind well to CD8ol(+) 
but not to CDSo~(-) CHO monolayers (Fig. 2). Blocking 
with the mouse anti-TLA mAb TL.m4 reduces the binding 
of CIR TL.J to a level equivalent to the mock-transfected 
CIR parent.  TL.m9, an isotype-matched  mouse mAb that 
does not recognize  the allelic variant  of TLA encoded by 
T18  a (30), does  not block binding  of CIR  TL.J  to  the 
CD8a(+) monolayer. Interestingly,  the rat anti-TLA mAb 
HD168  also does not block the binding, although cell sur- 
face staining of transfectants that express La/TLA chimeric 
molecules indicates that both HD168 and TL.m4 recognize 
an epitope encoded at least partially by the 7"18  a oel and o~2 
domains (data not shown). All three TLA-specific  mAbs have 
no effect on binding of either CIK A2.1 or CIK parent cells 
to the monolayers. Anti-CD8 mAbs 66.2 and 51.1, which 
were previously shown to block HLA-A2.1-mediated  binding 
to CDSo~(+) monolayers (28, 29), also block TLA-mediated 
binding (Fig. 2 and data not shown). This CD8 mAb blocking 
data argues that either TLA binds epitopes on human CD8c~ 
equivalent to those bound by human class I, as was also pre- 
viously suggested for mouse transplantation antigens K  b and 
DP (29), or that these antibodies sterically hinder more than 
one binding domain. 
The blocking of TLA-CDSoe adhesion by TL.m4 mAb 
is specific but could be due to the downregulation of TLA 
cell-surface expression upon antibody binding. Previously, 
downmodulation of surface TLA was shown to be depen- 
dent on a number of factors including temperature, with low 
temperature inhibiting modulation; cellular metabolism, with 
modulation inhibited by NAN3; and the cell-type expressing 
TLA, with downmodulation most readily detected in T cell 
leukemia lines (41, 42). However, flow cytometric analysis 
of CIR TL.J transfectants at 4~  and at 37~  in the buffer 
used for cell-cell binding assays showed no difference in peak 
or mean channel fluorescence intensity as compared  with 
TL.m4 staining used to determine high-expressing transfec- 
tants (data not shown). Also, when observed in the fluores- 
cence microscope, there was no evidence for either 'capping' 
or decreased antibody staining under the conditions used in 
the binding assays compared to conditions normally used to 
determine cell-surface  expression by flow cytometry  (data not 
shown).  The lack of TLA modulation could be due to the 
use of the fl-actin promoter in expressing TLA, the presence 
of NaN3 in the assay  buffer, the inability of exogenously in- 
troduced TLA genes in CIR B cells to be inhibited,  or per- 
haps a combination of these and other factors. 
Cytotoxic  T  Lymphocyte (CTL) Adhesion to Plate-Bound 
Thymus Leukemia Antigen (TLA) Glycoprotein.  Recently it 
was demonstrated that CD8-mediated binding of CTLs to 
purified mouse class I transplantation  antigens is activated 
via a TCR-mediated signal (33). In the absence of a TCR 
stimulus, which can be generated by soluble anti-TCR mAbs, 
CTL binding to purified, immobilized class I protein cannot 
be detected.  In the presence of soluble anti-TCK  mAb, a 
significant fraction  of the CTLs bind to any immobilized 
K- or D-locus protein.  Binding is independent of both the 
CTEs TCR specificity and polymorphic class I determinants, 
and is blocked by anti-Lyt-2 antibodies (33). Purified TLA 
was used to determine if it could function as a CD8 ligand 
in this TCR-activated  adhesion system. Unlike the cell-cell 
adhesion assay, this assay measures interactions with mouse 
CD8 oU3 heterodimers expressed at physiologic levels on T 
lymphocytes, and allows a semiquantitative  comparison  of 
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Figure 3.  Cloned CTLs are activated by anti-TCK mAb to bind to 
affinity-purified TLA glycoprotein.  (4) Purification of TLA by elution 
from an anti-TLA HD168 mAb affinity column. Buffer 1, used to remove 
nonspecifically adherent proteins, and buffer 2, used to specifically elute 
mAb bound  TLA from the column, are described  in Materials and Methods 
section. Eluted fractions were assayed for total protein content ( ....  ) 
and for TLA (  ). Fractions 30 to 40 were pooled yielding an en- 
riched preparation of approximately 25 #g/ml TLA. (B) CTL binding 
assay. The amount of input class I-enriched total protein per well, in/zgs, 
is expressed in parentheses on the abscissa. Control wells were coated with 
2% FCS. Results are expressed as % of cells bound as a result of activa- 
tion. Activated binding  (%) =  % cells bound  in the presence of anti-TCK 
mAb - % cells  bound in the absence  of anti-TCK mAb. Background binding 
in the absence of soluble F23.1 (35) mAb was 14% for C35 and 4% for 
Cll. Error bars depict the standard deviations of triplicate samples. 
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Figure 4.  The chimeric L~/TLA MHC class I molecule supports L  a 
alloreactive target call lysis. (A) Construct pHBAprLT18  d is depicted, not 
to scale. This construct was used to create the Ld/TLA transfectant  while 
the plasmid pL  d neo was used to create the L  d transfectant (not depicted). 
pBS is the cloning vector pBluescript KS+. (/3) Cytotoxicity assay using 
L cell transfectant and P815 mastocytoma (H-2  a) target cell lines. (A): 
mock (pSV2neo) transfectant; (O): L  d transfectant; (@): Ld/TL transfec- 
tam; and (U]): P815 mastocytoma  cells. Harvested  supernatants, representing 
one-half each well's total volume, were assayed for slCr content. Results 
are expressed as the percent lysis as a function of E/T ratio. Percent lysis 
(%) =  % total slCr release - % non-specific  slCr release. Error bars rep- 
resent the standard deviations of triplicate samples. 
TLA binding with binding results obtained for other class 
I molecules. TLA glycoprotein was purified from the CIR 
TL.J transfectant using an HD168 mAb affinity column (Fig. 
3 A). Contamination with HLA class I molecules is unlikely 
from CIR cells and,  furthermore even if present,  previous 
results suggest that human class I molecules probably would 
interact poorly with CD8 expressed on mouse CTLs (43). 
The purified TLA was directly immobilized on plastic mi- 
crotiter wells. As previously demonstrated for K and D  class 
I proteins (31), the immobilized TLA retained serologic de- 
terminants (Fig. 3 A) and remained associated with human 
32-microglobulin based on ELISA using the anti-3z-micro- 
globulin  mAb  BBM.1  (data  not  shown).  Two  different 
V38 +,  K b alloantigen-specific CTL clones were examined 
for binding. In both cases, purified TLA was observed to func- 
tion as a ligand for TCR-activated adhesion following stim- 
ulation with soluble anti-V/38 mAb F23.1  (Fig. 3 B).  The 
percent of T  cells bound was in the same range as that ob- 
tained using D- (Fig. 3 B) and K-locus encoded class I pro- 
teins as ligands (reference 33 and M. Mescher, unpublished 
results) at approximately equivalent protein concentrations 
used to coat the wells. These data suggest that the affinity 
of the TLA-CD8 interaction is similar to the affinity of K 
or D  for CD8. 
CD8-Dependent Cytotoxicity.  To determine  if the TLA- 
CD8 interaction can facilitate a CD8-dependent immune re- 
sponse, a chimeric class I gene was constructed with the pep- 
tide antigen-binding c~1 and or2 domains encoded by L a, and 
the or3, transmembrane,  and cytoplasmic domains encoded 
by T/8  a (Fig. 4 A). L a was chosen because primary, alloreac- 
tive La-specific CTLs are CD8 dependent and blockade with 
anti-L  a or anti-Lyt2 mAbs (44). As class I-CD8 binding is 
mediated by the o~3 domain by (3, 29), CD8 interactions with 
the chimeric molecule should  depend on TLA sequences. 
Before testing the La/TLA molecule as an alloantigen for 
primary CTLs, its ability to bind CD8 was assessed.  CIR 
transfectants that express the La/TLA chimeric class I mol- 
ecule bind human CD8c~(+) CHO monolayers as efficiently 
as HLA-A2.1-positive and TLA-positive transfectants in the 
cell-cell adhesion  assay (data not  shown). 
Table  1.  Blocking of Primary Cytotoxic T Lymphocyte (CTL) Lysis with Anti-Lyt-2  mAb 
Percent lysis 
Cell type  50:1"  50:1"#  25:1"  25:1"# 
Mock (pSV2neo)  15.7  _+  2.5  8.8  _+ 0.8  (43.9)  12.4  _+  2.4  3.9  _+  1.1  (68.5) 
L a  38.5  +  2.6  12.4  _+  1.8  (67.8)  23.9  +  1.1  9.5  _+ 0.4  (60.2) 
Ld/TLA  39.9  +  2.5  16.0  _+  3.8  (59.9)  27.4  _+ 0.7  11.4  +  0.3  (58.4) 
P815  (H-2  a)  69.3  _+ 3.9  31.8  -+  1.9  (54.1)  62.7  _+ 6.4  18.3  _+ 4.1  (70.1) 
* Effector/target  ratio. 
% lysis with mAb 41-3.48 incubation. 
Parentheses indicate % inhibition by mAb blocking. 
mAB 41-3.48 blocking of anti-H-2  a primary CTL lysis of four L cell target lines. The % inhibition is calculated as [(% lysis unblocked - % lysis 
blocked)/  % lysis unblocked]  x  100. 
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Cluster  I  (direct binding)  Cluster  2  Cluster 3 
(223  224  225  226  227  228  229)  (233  235)  (245  247) 
HLA-A2.1  D  Q  T  Q  D  T  E  T  P  A  V 
T18  a  E  L  I  Q  D  T  E  T  P  A  V 
Q7  d  E  L  T  Q  D  T  E  T  P  A  V 
H-2K  b  E  L  I  Q  D  M  E  T  P  A  V 
Consensus"  Q/E  Q/L  T(I)  Q  D  T/M  E  T  P  A  V 
The amino acid positions listed are those that comprise the minimal o~3 domain binding site as determined for HLA-A2.1 by Salter et al. (3). The 
amino acid at each position for four class I molecules and the consensus sequence are denoted by the standard single-htter code and were obtained 
from a compilation by Klein and Figueroa (18). *Consensus denotes a sequence based upon 23 class I human and mouse o~3 domains with the amino 
acid before the slash mark at each position found in the human and that after the slash mark found in the mouse. The parentheses at position 225 
indicates that a minority of both human and mouse class I molecules have I instead of T. 
Primary anti-H-2  d CTLs were generated by in vitro cul- 
ture  of H-2  b splenocytes with  irradiated  BALB/c  (H-2  a) 
stimulators and tested for H-2a-specific  cytotoxicity using 
P815  (H-2  a)  mastocytoma  targets  (Fig.  4  B).  A  small 
amount of cytolysis was observed against mock-transfected 
L cell targets, perhaps due to cross-reactivity of primed effectors 
that can also recognize H-2  k targets. Ld-specific cytotoxicity 
was measured using L cell (H-2  k) transfectant targets that 
express equivalent amounts of either L d or the Ld/TLA chi- 
meric molecule. Transfectants expressing Ld/TLA are lysed 
as efficiently as those expressing L d at  all  of the effector: 
target ratios tested (Fig. 4 B). Furthermore, the level of inhi- 
bition of target lysis by incubation with the anti-CD8 mAb 
41-3.48  is  similar  if  the  target  cells  express  either  the 
Ld/TLA molecule or the L d alloantigen (Table 1). In sum, 
these results suggest that the TLA or3 domain is capable of 
delivering the appropriate signal(s) through CD8 binding for 
a CTL response, and that the TISd-encoded o~3, transmem- 
brane, and cytoplasmic domains do not impede the normal 
functioning of a class I molecule during this alloantigenic 
response. 
Discussion 
If the hypothesis that class Ib molecules present antigens 
were correct, it should be possible to demonstrate that these 
proteins carry out functions similar to those of the class I 
transplantation  antigens,  including appropriate  trafficking 
through the cell, loading of peptide antigen, and interaction 
with the TCK and CD8. It is particularly necessary to estab- 
lish this for the TLA molecule, which has not been observed 
to participate in cell-mediated immune responses.  In this re- 
port, it is demonstrated that TLA binds to human and mouse 
CDS, and that a chimeric molecule containing the COOH- 
terminal portion of TLA can support a CD8-dependent rec- 
ognition of the L d alloantigen. 
Previously reported results from our laboratory showed that 
TLA  is  highly expressed by both  epithelial cells  and in- 
traepithelial lymphocytes (IELs) in the mouse small intestine 
(20). IELs are greater than 80% CD8 single-positive and ap- 
proximately 50% of them express the 3'/~ TCK (45-47). The 
ability of TLA to bind effectively to CD8 supports the hy- 
pothesis that it may be involved in antigen presentation to 
either TCR 3~(+) and/or c~(+) IELs, although a critical 
test of this hypothesis will require the detection of antigen- 
specific TLA-restricted IELs. TLA is highly expressed by im- 
mature cortical thymocytes, most of which also express CD8. 
It is therefore possible that TLA-CD8 interactions occur in 
the thymus, and these interactions may have important con- 
sequences for T  celt differentiation. 
Using site-directed mutagenesis, a minimal consensus se- 
quence encompassing at least 11 amino acids in the human 
MHC class I c~3 domain has been defined that is required 
for binding to transfectants that express high levels of human 
CDSc~ (reference 3 and Table 2). The c~3 domain has a con- 
formation similar to an immunoglobulin constant region ho- 
mology unit, and most of the critical amino acids for CD8 
binding, including positions 223-229,  233, and 235, are on 
an external-facing loop connecting two antiparallel B strands 
(3).  Interestingly, many class Ib molecules possess  this c~3 
domain minimal sequence, or sequences that deviate from 
it only slightly. For example, compared to HLA-A2.1, TLA 
contains conservative amino acid substitutions at positions 
223-225 and complete identity at positions 226-229, 233, 235, 
245, and 247. TLA differs from H-2K  b only at position 228 
in this minimal sequence. In fact, a compilation of 23 mouse 
and human class I c~3 domain sequences suggests that these 
11 amino acids are extremely well conserved (reference 18 
and see the consensus sequence of Table 2). 
The relatively high degree of sequence conservation be- 
tween different MHC class I c~3 binding domains suggests 
that other class Ib proteins in addition to TLA may also bind 
CDS.  However, it is probably not possible to infer CD8 
binding from the presence of the conserved, minimal o~3 do- 
main sequence alone. The Q7d-encoded o~3 domain retains 
the minimal consensus sequence for CD8 binding (Table 2). 
1136  Thymus Leukemia Antigen Binds CD8 Yet,  this c~3 domain is incapable of supporting  a primary 
CTL response directed at a Ld/Q7a(oL3)/L d chimeric mole- 
cule,  in  which  sequences  other  than  or3  are  encoded  by 
Ld(48). Secondary CTL responses directed at this chimeric 
molecule, which are less CD8 dependent, can be obtained. 
These data suggest that the QTao~3 domain is incapable of 
binding CD8 in a manner that allows a primary alloreactive 
response. Therefore, in the absence of experimental evidence, 
it cannot be assumed that any class Ib molecule other than 
TLA binds  to CD8. 
The  hypothesis that  class  Ib molecules present  antigens 
to TCR ?&positive lymphocytes does not require that  all 
of these molecules interact with CDS. Most -)/~-positive T 
cells,  including the few known to recognize class Ib mole- 
cules  (5,  12,  13),  are  CD4/CD8  double-negative.  These 
double-negative ")8 T cells do not require CD8 as a co-receptor, 
despite the apparent evolutionary conservation of the min- 
imal CD8 binding site in class Ib molecules.  In contrast, nearly 
all of the TCR ")&positive IELs of the mouse small intestine 
express CD8, which could act as a co-receptor if the TCKs 
expressed by these cells recognize an antigen  presented by 
the TLA molecule. 
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